FMS: Fresenius Medical Care AG & Co. KGaA - Summary | Jitta

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

End of day
Aug 13, 2018
Price
$48.09
Loss Chance
43.6%
4.40
Updated 2018Q2
4 months ago
Aug 03, 2018
JITTA SCORE
9.81%Above Jitta Line
Jitta Ranking
67 / 795
United States
?
NASDAQ, NYSE
1,351 / 4,758
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (50)
Recent Business Performance (47)
Financial Strength (70)
Return to Shareholders (77)
Competitive Advantage (54)
Jitta Signs
Revenue and Earning
201220132014201520162017
Revenue22.9524.7026.5827.4828.4734.82
Normalized Earning1,161.931,109.891,045.271,076.941,203.761,535.99
EPS1.891.841.721.761.972.51
Consistent
Recent Business Performance
Earning per ShareQ1Q2Q3Q4
20180.560.62--
20170.540.490.600.77
20160.400.480.560.62
Earning Growth Last Year
Dividend Payout
20132014201520162017
Dividend Per Share0.530.470.430.510.64
Dividend to Net Profit0.270.300.250.210.23
Every year
Key Stats
Jitta Score
Jitta Line
4.40
9.81%
2.44
0.48%
Healthcare Services
COMPANY DESCRIPTION
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist and intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; and offers non-dialysis products, including acute cardiopulmonary and apheresis products. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2017, it operated 3,752 outpatient dialysis clinics in approximately 50 countries. The company has operations in Germany, the United States, and internationally. Fresenius Medical Care AG & Co. KGaA was founded in 1996 and is headquartered in Bad Homburg, Germany.